46
Participants
Start Date
June 6, 2020
Primary Completion Date
May 10, 2021
Study Completion Date
June 8, 2021
Ibrutinib
Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.
Placebo
Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.
Duplicate_GW Medical Faculty Associates /ID# 222023, Washington D.C.
University of Miami /ID# 223227, Miami
Midway Immunology and Research /ID# 222004, Ft. Pierce
Intermountain Healthcare /ID# 221955, Salt Lake City
Stanford University School of Med /ID# 221954, Stanford
Medstar Washington Hospital Center /ID# 221886, Washington D.C.
Triple O Research Institute /ID# 222944, West Palm Beach
Brigham & Women's Hospital /ID# 221847, Boston
Beth Israel Deaconess Medical Center /ID# 222994, Boston
Lead Sponsor
Janssen Research & Development LLC; Pharmacyclics LLC (An AbbVie Company)
UNKNOWN
AbbVie
INDUSTRY